section name header

Pronunciation

bis-OH-proe-lol

Classifications

Therapeutic Classification: antihypertensives

Pharmacologic Classification: beta blockers

Indications

REMS


Action

  • Blocks stimulation of beta1(myocardial)-adrenergic receptors. Does not usually affect beta2(pulmonary, vascular, uterine)-receptor sites.
Therapeutic effects:
  • Decreased BP and heart rate.

Pharmacokinetics

Absorption: Well absorbed after oral administration, but 20% undergoes first-pass hepatic metabolism.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: 50% excreted unchanged by the kidneys; remainder renally excreted as metabolites; 2% excreted in feces.

Half-Life: 9–12 hr.

Time/Action Profile

(antihypertensive effect)

ROUTEONSETPEAKDURATION
POunknown1–4 hr24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: BRADYCARDIA, HF, hypotension, peripheral vasoconstriction

Derm: rash

EENT: blurred vision, stuffy nose

Endo: hyperglycemia, hypoglycemia

GI: liver enzymes, constipation, diarrhea, nausea, vomiting

GU: erectile dysfunction, libido, urinary frequency

MS: arthralgia, back pain, joint pain

Neuro: fatigue, weakness, anxiety, depression, dizziness, drowsiness, insomnia, memory loss, mental status changes, nervousness, nightmares

Resp: bronchospasm, PULMONARY EDEMA, wheezing

Misc: drug-induced lupus syndrome

Interactions

Drug-drug:

Route/Dosage

Renal Impairment

Hepatic Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Zebeta